Dr. Yuyi Shen, Principal Scientist, Grifols, talks about the benefits of modeling downstream disruptive technologies to improve downstream bioprocessing and evaluating the financial impact of implementing these technologies.

Modeling Downstream Disruptive Technologies to Improve Downstream Bioprocessing.

The Downstream Column (DsC) is an online publication targeting members of the biologics industry. Our intent is to provide a community to share expertise and best practices as well as discuss topics of interest. The Downstream Column covers areas important to the research, discovery, development, and manufacture of biologic therapeutics. Key industry coverage areas include: purification, formulation, fill/finish and QA/QC for cell and gene therapies, vaccines, biologics, and emerging therapeutic modalities.

Share Modeling Downstream Disruptive Technologies to Improve Downstream Bioprocessing.

Sign up to save your podcasts

Modeling Downstream Disruptive Technologies to Improve Downstream Bioprocessing.

Modeling Downstream Disruptive Technologies to Improve Downstream Bioprocessing.